Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells.

Autor: Desai N; Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Telangana, India., Hasan U; Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Telangana, India; Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Telangana, India., K J; Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Telangana, India., Mani R; Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Telangana, India., Chauhan M; Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Telangana, India., Basu SM; Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Telangana, India., Giri J; Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Telangana, India. Electronic address: jgiri@bme.iith.ac.in.
Jazyk: angličtina
Zdroj: Acta biomaterialia [Acta Biomater] 2023 Apr 15; Vol. 161, pp. 1-36. Date of Electronic Publication: 2023 Mar 10.
DOI: 10.1016/j.actbio.2023.03.004
Abstrakt: Immunotherapy involves the therapeutic alteration of the patient's immune system to identify, target, and eliminate cancer cells. Dendritic cells, macrophages, myeloid-derived suppressor cells, and regulatory T cells make up the tumor microenvironment. In cancer, these immune components (in association with some non-immune cell populations like cancer-associated fibroblasts) are directly altered at a cellular level. By dominating immune cells with molecular cross-talk, cancer cells can proliferate unchecked. Current clinical immunotherapy strategies are limited to conventional adoptive cell therapy or immune checkpoint blockade. Targeting and modulating key immune components presents an effective opportunity. Immunostimulatory drugs are a research hotspot, but their poor pharmacokinetics, low tumor accumulation, and non-specific systemic toxicity limit their use. This review describes the cutting-edge research undertaken in the field of nanotechnology and material science to develop biomaterials-based platforms as effective immunotherapeutics. Various biomaterial types (polymer-based, lipid-based, carbon-based, cell-derived, etc.) and functionalization methodologies for modulating tumor-associated immune/non-immune cells are explored. Additionally, emphasis has been laid on discussing how these platforms can be used against cancer stem cells, a fundamental contributor to chemoresistance, tumor relapse/metastasis, and failure of immunotherapy. Overall, this comprehensive review strives to provide up-to-date information to an audience working at the juncture of biomaterials and cancer immunotherapy. STATEMENT OF SIGNIFICANCE: Cancer immunotherapy possesses incredible potential and has successfully transitioned into a clinically lucrative alternative to conventional anti-cancer therapies. With new immunotherapeutics getting rapid clinical approval, fundamental problems associated with the dynamic nature of the immune system (like limited clinical response rates and autoimmunity-related adverse effects) have remained unanswered. In this context, treatment approaches that focus on modulating the compromised immune components within the tumor microenvironment have garnered significant attention amongst the scientific community. This review aims to provide a critical discussion on how various biomaterials (polymer-based, lipid-based, carbon-based, cell-derived, etc.) can be employed along with immunostimulatory agents to design innovative platforms for selective immunotherapy directed against cancer and cancer stem cells.
Competing Interests: Declaration of Competing Interest The authors declare that they do have any conflict of interest.
(Copyright © 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: